VENUSREM

** Shares of Venus Remedies VENR.NS rise as much as 17.21% to 426 rupees, highest since Aug 2024

** Stock last up 11.6%; trading volume at ~15x the 30-day avg, with stock set for most active session since Feb 6

** Pharma firm's March-qtr net profit doubles to 210 mln rupees ($2.5 mln); rev little changed; total costs fall 6%

** Stock now up ~14 YTD

($1 = 85.3500 Indian rupees)

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

April 17 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LTD - US FDA GRANTS QIDP DESIGNATION TO VENUS REMEDIES' VRP-034

Source text: ID:nBSE93HMNh

Further company coverage: VENR.NS

(([email protected];))

** Venus Remedies VENR.NS climbs as much as 4.4% to 320 rupees

** Pharma firm gets exclusive in-licensing rights from UK-based Infex Therapeutics to develop, market anti-infection drug MET-X in India

** No financial details have been disclosed

** Stock last up 2.6%, trimming YTD losses to ~4%

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

** Venus Remedies' stock VENR.NS jump as much as 12.5% to 332.4 rupees; biggest intraday gain since mid-June

** Stock last up ~8% after pharma co renews European Good Manufacturing Practices (GMP) certification for Portugal plant

** Stock on track to log busiest trading session since early-Dec, with volume 3.5x the 30-day avg

** It lost ~22% in 2024 vs 124% gains in 2023

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Jan 20 (Reuters) - Venus Remedies Ltd VENR.NS:

• RENEWS EU GMP CERTIFICATION

Source text: ID:nBSEbnVnH0

Further company coverage: VENR.NS

(([email protected];;))

** Shares of Venus Remedies VENR.NS rise as much as 4.8% to 324.95 rupees

** Pharmaceutical co says it got good manufacturing practice (GMP) certification from Moldova, which will help Eastern European expansion

** Stock on track for a third consecutive session of gain

** More than 35,000 shares change hands, 1.5x of 30-day avg

** Stock down 21.1% YTD

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Venus Remedies VENR.NS rises 7.8% to 348.30 rupees

** Pharmaceutical co secures marketing authorization for Pemetrexed 500 mg in Philippines

** Pemetrexed is a chemotherapeutic agent widely used in treatment of lung cancer and mesothelioma

** Trading vols at 65,031, 1.8x the 30-day avg

** Stock tims YTD losses to ~14%

(Reporting by Vijay Malkar)

(([email protected];))

** Shares of Venus Remedies VENR.NS rise as much as 2.4% to 314 rupees

** Drug maker on Friday said it will establish a unit in Hungary via its wholly owned subsidiary Venus Pharma GmbH, Germany to enhance market presence in Eastern Europe

** Stock fell 1.5% in Nov., its fourth straight monthly fall

** Stock last up 1.4%, trimming YTD loss to 23.5%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Nov 29 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES - APPROVED SET UP OF HUNGARY UNIT TO EXPAND EASTERN EUROPE MARKET PRESENCE

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS up as much as 5% to 395 rupees, highest since Feb 15

** Drug maker on Wednesday said it won a contract from Pan American Health Organisation for supplying essential cancer drugs to multiple Latin American countries

** Stock pares some gains; last up 2%

** Including day's gains, VENR down ~6% YTD vs 18% surge in pharma index .NIPHARM

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

** Shares of India's Venus Remedies VENR.NS rise as much as 8.7% to 385 rupees, currently up ~6%

** Pharma co receives order from United Nations Children's Fund (UNICEF) for its antibiotic drug, Ceftriaxone 1gm

** Co did not disclose financial details of the order

** Trading vols 6.2x the 30-day avg

** VENR has lost 7.8% so far this year after surging 124% in 2023

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

May 30 (Reuters) - Venus Remedies Ltd VENR.NS:

• MARCH-QUARTER CONSOL NET PROFIT 105.1 MILLION RUPEES VERSUS PROFIT 110.6 MILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.95 BILLION RUPEES VERSUS 1.56 BILLION RUPEES

Source text for Eikon: ID:nBSE52pZH9

Further company coverage: VENR.NS

(([email protected];))

April 1 (Reuters) - Venus Remedies Ltd VENR.NS:

• AWARDED 25 MILLION RUPEES AS REMAINING PART OF FIRST INCENTIVE UNDER PRODUCTION LINKED INCENTIVE SCHEME

Source text for Eikon: ID:nBSE2q5KJm

Further company coverage: VENR.NS

(([email protected];;))

March 11 (Reuters) - Venus Remedies Ltd VENR.NS:

• SECURED GOOD MANUFACTURING PRACTICES (GMP ) APPROVAL FROM UNICEF

• MANUFACTURING UNIT IN BADDI APPROVED TO SUPPLY UNICEF WITH CEPHALOSPORIN ANTIBIOTICS

Source text for Eikon: ID:nBSE5jR9WN

Further company coverage: VENR.NS

(([email protected];))

March 8 (Reuters) - Venus Remedies Ltd VENR.NS:

• RECEIVES MARKETING AUTHORIZATIONS FOR ONCOLOGY DRUGS IN UKRAINE

Source text for Eikon: ID:nBSE1ZJB1N

Further company coverage: VENR.NS

(([email protected];))

March 6 (Reuters) - Venus Remedies Ltd VENR.NS:

• AWARDED ITS FIRST DISBURSEMENT OF 75 MILLION RUPEES UNDER PRODUCTION LINKED INCENTIVE SCHEME

Further company coverage: VENR.NS

(([email protected];))

Feb 14 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LTD DEC-QUARTER CONSOL NET PROFIT 68.5 MILLION RUPEES VERSUS 32.9 MILLION RUPEES

• VENUS REMEDIES LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 1.43 BILLION RUPEES VERSUS 1.17 BILLION RUPEES

Source text for Eikon: ID:nBSE3vZ8DB

Further company coverage: VENR.NS

(([email protected];))

Jan 18 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LIMITED ATTAINS GMP CERTIFICATION FROM LIBYA

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS rise as much as 4.18% to 425 rupees; stock last up 3.2%

** Pharma company receives new marketing authorizations for two drugs in Malta, Europe

** Approvals to help in expanding global reach, says VENR

** Trading volume is 123,997 shares as of 12:05 p.m. IST, 1.1x the 30-day avg - LSEG data

** VENR shares up 4.4% in January so far, after jumping 124.32% in 2023

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of pharma company Venus Remedies VENR.NS rise as much as 8.6% to 408.7 rupees, their steepest climb in a month

** VENR gets marketing authorisations for chemotherapy medications

Docetaxel In Israel And Cytarabine in Colombia

** Stock last up 6.3%, bumping YTD gains to 121%

(Reporting by Anisha Ajith)

(([email protected];))

Dec 20 (Reuters) - Venus Remedies Ltd VENR.NS:

• FORAYS INTO WELLNESS ARENA

Further company coverage: VENR.NS

(([email protected];))

Dec 18 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LTD - SUCCESSFULLY OBTAINED THREE NEW MARKETING AUTHORIZATIONS FOR ENOXAPARIN FROM BAHRAIN

Source text for Eikon: ID:nBSE6jNMDN

Further company coverage: VENR.NS

(([email protected];;))

Dec 5 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES GRANTED MARKET AUTHORIZATION FOR ENOXAPARIN IN AZERBAIJAN

Source text for Eikon: ID:nBSEQjGk2

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS up as much as 4.9% at 405 rupees

** Pharmaceutical formulations maker receives marketing authorisation for osteoporosis drug Zoledronic Acid and chemotherapy medicine Paclitaxel in Phillipines

** VENR also gets marketing authorisation for cancer drug Bleomycin in Saudi Arabia

** Over 164,000 shares traded, 0.9x the 30-day moving average

** Stock more than doubled so far this year

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Nov 9 (Reuters) - Venus Remedies Ltd VENR.NS:

• INDIA'S VENUS REMEDIES LTD SEPT-QUARTER CONSOL NET PROFIT 99.4 MILLION RUPEES VERSUS PROFIT 53.3 MILLION RUPEES

• VENUS REMEDIES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.68 BILLION RUPEES VERSUS 1.40 BILLION RUPEES

Source text for Eikon: ID:nNSE1SXtMd

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS rise as much as 6.22% to 279.90 rupees apiece

** Stock on course to snap a four-day losing streak, if gains hold

** The pharmaceutical formulations maker receives "three star export house" certificate from Indian government

** Certification bestowed upon companies that consistently report export growth and contribute to country's foreign trade

** Three-star export houses get benefits of Accredited Clients Programme, under Central Board of Excise and Customs (CBIC) guidelines

** Three-star export houses also eligible to export some items on free of cost basis for export promotion

** VENR up 49% YTD - LSEG data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Venus Remedies VENR.NS surge as much as 9.29% to 258.15 rupees per share, before erasing gains amid selling pressure in markets

** Pharmaceutical company's unit receives market authorisation in the United Kingdom for Bleomycin, a drug used in chemotherapy to treat cancer

** VENR now has a total of 15 market authorisations globally for the chemotherapy drug

** Trading volume is 103,645 shares as of 10:46 a.m. IST, twice the 30-day avg - LSEG data

** Including day's gains, VENR shares up 31.3% in 2023 so far

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463))

** Venus Remedies' shares VENR.NS rise 4% to 236.55 rupees

** CO says got marketing approval for six key chemotherapy drugs from the Philippines

** Adds also got approval to market chemotherapy drug oxaliplatin from Myanmar

** Over 48,000 shares traded, 2x their 30-day moving avg

** Including day's gains, stock has risen ~31% YTD

(Reporting by Rama Venkat in Bengaluru)

(([email protected]; https://twitter.com/ramavenkat0607;))

Sept 20 (Reuters) - Venus Remedies Ltd VENR.NS:

• CO EXTENDS ITS ONCOLOGY PORTFOLIO IN SOUTH EASTERN EUROPE WITH SERBIAN MARKETING APPROVAL FOR GEMCITABINE, DOCETAXEL

Further company coverage: VENR.NS

(([email protected];))

Sept 13 (Reuters) - Venus Remedies Ltd VENR.NS:

• GETS DEPARTMENT OF SCIENTIFIC AND INDUSTRIAL RESEARCH REGISTRATION FOR CUSTOMS DUTY EXEMPTION

Source text for Eikon: ID:nBSE8w0VBW

Further company coverage: VENR.NS

(([email protected];))